Low-dose aspirin and breast cancer risk
Author Information
Author(s): Zhang S M, Cook N R, Manson J E, Lee I-M, Buring J E
Primary Institution: Brigham and Women's Hospital, Harvard Medical School
Hypothesis
Does low-dose aspirin reduce the risk of breast cancer based on tumor characteristics?
Conclusion
The study found that low-dose aspirin does not have a preventive effect on breast cancer.
Supporting Evidence
- Low-dose aspirin treatment had no significant effect on risk of total breast cancer.
- The study included a large sample size of nearly 40,000 women.
- Results were consistent across various tumor characteristics.
- Follow-up for morbidity and mortality was over 97% complete.
Takeaway
Taking low-dose aspirin doesn't help prevent breast cancer, even for different types of tumors.
Methodology
The study was a randomized trial with 39,876 women, comparing low-dose aspirin to placebo over an average of 10 years.
Potential Biases
The study design minimizes bias, but there could still be unmeasured confounding factors.
Limitations
The study may not account for all potential confounding factors and the effect of aspirin might vary with different doses.
Participant Demographics
Women aged 45 and older with no history of cancer or cardiovascular disease.
Statistical Information
P-Value
0.68
Confidence Interval
0.88–1.08
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website